RESUMEN
Transitional cell carcinoma of the urinary bladder is the second most common genitourinary malignancy in people in the United States. Cyclooxygenase-2 (COX-2) is overexpressed in bladder cancer. COX-2 inhibitors have had antitumor activity against bladder cancer, but the mechanisms of action are unclear. Clinically relevant concentrations of COX-2 inhibitors fail to inhibit proliferation in standard in vitro assays. In pilot experiments, different culture conditions [standard monolayer, modified monolayer, soft agar, collagen, and poly(2-hydroxyethyl methacrylate)-coated plates] were assessed to determine conditions suitable for the study of COX inhibitor growth-inhibitory effects. This was followed by studies of the effects of clinically relevant concentrations of a selective COX-2 inhibitor (celecoxib) on urinary bladder cancer cell lines (HT1376, TCCSUP, and UMUC3). Celecoxib (Asunto(s)
Apoptosis/efectos de los fármacos
, Carcinoma de Células Transicionales/tratamiento farmacológico
, Proliferación Celular/efectos de los fármacos
, Inhibidores de la Ciclooxigenasa 2/farmacología
, Pirazoles/farmacología
, Sulfonamidas/farmacología
, Neoplasias de la Vejiga Urinaria/tratamiento farmacológico
, Western Blotting
, Celecoxib
, Línea Celular Tumoral
, Ciclooxigenasa 2/metabolismo
, Dinoprostona/metabolismo
, Citometría de Flujo
, Humanos
, Proyectos Piloto
, Ensayo de Tumor de Célula Madre
RESUMEN
Combination chemotherapy is superior to single-agent chemotherapy for treating canine lymphoma, but the effect of each drug on efficacy remains unknown. By comparing 34 dogs treated with a modified cyclophosphamide, vincristine, prednisone (COP) chemotherapy protocol and 42 dogs given asparaginase in the induction phase of the same protocol, the effect of asparaginase on the chemotherapeutic protocol was determined. Both groups were compared based on clinical response at 2 weeks and 6 weeks, and on the progression-free interval. Asparaginase did not significantly increase the likelihood of a clinical remission or prolong the initial progression-free interval in the dogs studied.